Allergic contact dermatitis caused by dorzolamide eyedrops

Código QR

Allergic contact dermatitis caused by dorzolamide eyedrops

Seung-Jun Lee, Moosang KimDepartment of Ophthalmology, School of Medicine, Kangwon National University, Chuncheon, KoreaAbstract: The side effects of topical dorzolamide hydrochloride, such as conjunctivitis, eyelid edema, and eye lid irritation, are well known. However, allergic contact dermatitis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee SJ, Kim M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/1e5c5e7f13604a078c1c6e1c0760f9a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy of two-month treatment with Xiloial&reg; eyedrops for discomfort from disposable soft contact lenses
por: Piera Versura, et al.
Publicado: (2010)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda S, et al.
Publicado: (2014)

Tetracaine 0.5% eyedrops with or without lidocaine 2% gel in topical anesthesia for cataract surgery
por: Anthoula T Tsoumani, et al.
Publicado: (2010)

Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal
por: Suzuki T, et al.
Publicado: (2013)

Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations [Corrigendum]
por: Feng A, et al.
Publicado: (2017)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Yoshimi Nakamura, et al.
Publicado: (2009)

Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution
por: Fernandez KB, et al.
Publicado: (2015)

Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure
por: Takeda S, et al.
Publicado: (2014)

Rational use of the fixed combination of dorzolamide &ndash; timolol in the management of raised intraocular pressure and glaucoma
por: Jason Yeh, et al.
Publicado: (2008)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
por: Kenji Inoue, et al.
Publicado: (2011)

Comparative assessment of the cytotoxicity of six anti-inflammatory eyedrops in four cultured ocular surface cell lines, as determined by cell viability scores
por: Ayaki M, et al.
Publicado: (2012)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Nicholas P Bell, et al.
Publicado: (2010)

Clinical experiences in fungal keratitis caused by Acremonium
por: Kim SJ, et al.
Publicado: (2014)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Moisseiev E,&nbsp;Lazar M, et al.
Publicado: (2012)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness
por: Bremond-Gignac D, et al.
Publicado: (2015)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue K, et al.
Publicado: (2014)

An upright eyedrop bottle: accuracy, usage of excess drops, and contamination compared to a conventional bottle
por: Davies IJ, et al.
Publicado: (2016)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini R, et al.
Publicado: (2015)

Patient perspectives when switching from Cosopt&reg; (dorzolamide-timolol) to Azarga&trade; (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger GA, et al.
Publicado: (2012)

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension
por: Cindy Hutnik, et al.
Publicado: (2010)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue K, et al.
Publicado: (2015)

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops
por: Eiichi Uchio
Publicado: (2008)

Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
por: Shimizu Y, et al.
Publicado: (2015)

Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
por: Jeremy B Wingard, et al.
Publicado: (2011)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann MT, et al.
Publicado: (2014)

Incidence of retinal detachment associated with atopic dermatitis in Japan: review of cases from 1992 to 2011
por: Sasoh M, et al.
Publicado: (2015)

A patient preference comparison of Azarga&trade; (brinzolamide/timolol fixed combination) vs Cosopt&reg; (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Thomas K Mundorf, et al.
Publicado: (2008)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

High Dk piggyback contact lens system for contact lens-intolerant keratoconus patients
por: Tomris Sengor, et al.
Publicado: (2011)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu DI, et al.
Publicado: (2015)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Patricia B Williams, et al.
Publicado: (2010)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen G, et al.
Publicado: (2015)

Multipurpose soft contact lens care in Japan
por: Toshida H, et al.
Publicado: (2012)

Melanocytoma of the ciliary body misdiagnosed as iridodialysis
por: Kim M, et al.
Publicado: (2014)

The clinical and cellular basis of contact lens-related corneal infections
por: Danielle M Robertson, et al.
Publicado: (2008)